Progress in mechanistic and clinical translational research of endothelin A receptor antagonists in the treatment of diabetic kidney disease: a narrative review
Muqin Li, Chenyang Xie, Yue Qiu, Xiaoyue Li, Guanjun Han, Ning Ma, Guofeng Wang · 2026
Read Progress in mechanistic and clinical translational research of endothelin A receptor antagonists in the treatment of diabetic kidney disease: a narrative review by Muqin Li, Chenyang Xie, Yue Qiu, Xiaoyue Li, Guanjun Han, Ning Ma, Guofeng Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13218956.txt.
Description
Muqin Li and co-authors review in a 2026 paper receptor blockers as a fresh line of attack on diabetic kidney disease. The disease still leads causes of kidney failure worldwide despite three drug classes in wide use. A vessel tightening signal, acting through its A receptor, drives glomerular harm and scarring.
Animal studies show blocking that receptor eases pressure in the filter units and saves their lining cells. Inflammation and scar signaling also cool under blockade in those models. In the SONAR trial, one blocker cut renal event risk to a hazard ratio near 0.65. Urine protein ratios fell 30% to 40% in picked responder patients there. The review weighs safety and translation gaps for wider use.
Catalog record
| CREATOR | Muqin Li, Chenyang Xie, Yue Qiu, Xiaoyue Li, Guanjun Han, Ning Ma, Guofeng Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |